Alpha Mannosidosis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

According to Mordor Intelligence, the alpha mannosidosis market size is estimated at USD 433.10 million in 2025 and is expected to reach USD 938.50 million by 2030, at a CAGR of 16.40% during the forecast period (2025-2030).

This report is Segmented by Therapy Type (Enzyme Replacement Therapy, Hematopoietic Stem-Cell Transplantation, and More), Route of Administration (Intravenous Infusion, Surgical Transplant Administration, Intrathecal/CNS-direct Delivery, and More), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Alpha Mannosidosis Market Trends and Insights

Post-Approval Uptake of Velmanase Alfa ERT

Lamzede's June 2024 FDA approval unlocked commercial access for US patients who had relied on importation or compassionate use. Trial data showed a 77.6% reduction in serum oligosaccharides at 52 weeks, and the SPARKLE registry will track outcomes over 15 years, reinforcing prescriber confidence. Earlier pediatric initiation correlates with improved hearing and immune profiles, prompting guideline updates that advocate treatment soon after diagnosis.Weekly infusions require specialized centers, but growing home-care programs mitigate logistical burden for stable patients. Rapid US uptake thus adds meaningful near-term volume to the alpha-mannosidosis market.

Increasing Newborn-Screening Pilots for Lysosomal Storage Disorders

Large-scale pilots in China uncovered lysosomal storage disorders in 1 in 1,512 births, validating next-generation sequencing coupled with tandem-mass-spectrometry reflex testing. New Jersey's experience covering 438,515 newborns demonstrates operational feasibility in a US setting. Tuscany's inclusion of metachromatic leukodystrophy proves European payers' willingness to broaden rare-disease panels. Earlier detection shifts treatment to pre-symptomatic stages, maximizing therapeutic benefit and curbing long-term costs, arguments now resonating with policymakers. As more jurisdictions legislate universal screening, the alpha-mannosidosis market captures incremental patients who would previously have remained undiagnosed.

High Annual Treatment Cost & Pricing Pushback

Weekly velmanase alfa infusions translate into yearly drug spend above USD 650,000, a burden that challenges single-payer and emerging-market budgets. Gene-therapy benchmarks, such as Lenmeldy's USD 4.25 million launch price, heighten affordability concerns for one-time cures. Central and Eastern Europe report fewer than 20 reimbursed orphan medicines, underscoring access gaps within the very region that originally adopted Lamzede. Insurers increasingly demand outcome-based contracts linking payment to long-term functional benefits, shifting financial risk back to manufacturers. Without innovative financing, sticker shock will limit near-term uptake, slowing growth in the alpha-mannosidosis market.

Other drivers and restraints analyzed in the detailed report include:

1. Gene-Therapy Pipeline Breakthroughs
2. Expansion of Compassionate-Use & Early-Access Programs
3. Limited Blood-Brain-Barrier Penetration of Current ERT

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The enzyme-replacement segment represented 82.4% of the alpha-mannosidosis market in 2024, anchored by velmanase alfa's first-to-market advantage. Gene therapies, buoyed by six pediatric-disease designations and venture-capital inflows, are forecast to post an 18.4% CAGR through 2030, setting a disruptive tone. Hematopoietic stem-cell transplants secure clinical relevance for severe neurologic phenotypes, with post-2000 survival at 86% versus 64% pre-2000. Supportive multidisciplinary care-including audiology, immunology, and physiotherapy-expands as standard protocols mature. Pharmacological-chaperone candidates seek to correct misfolded lysosomal enzymes, though none have yet reached pivotal trials.

Robust real-world registry data underscore velmanase alfa durability, convincing payers of sustained clinical return. However, single-dose AAV vectors threaten recurring-revenue models, compelling Chiesi to diversify via grants that fund next-generation research. SmartPharm's gene-encoded-enzyme platform illustrates hybrid approaches that could lengthen expression without permanent genome integration. As these modalities converge, the alpha-mannosidosis market will increasingly reward therapies that pair CNS reach with simplified administration schedules.

Complete Report Scope:

• By Therapy Type
  • Enzyme Replacement Therapy
  • Hematopoietic Stem-Cell Transplantation
  • Gene Therapy
  • Supportive & Adjunctive Care
  • Investigational Pharmacological Chaperones
• By Route of Administration
  • Intravenous Infusion
  • Surgical Transplant Administration
  • Intrathecal / CNS-direct Delivery
  • Systemic Viral Vector Delivery
  • Other Routes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Europe, with a 41.3% revenue share in 2024, benefits from EMA's 2018 approval of velmanase alfa and well-established orphan-drug reimbursement mechanisms. Germany and France each reimburse more than 100 rare-disease medicines, fostering early and sustained uptake. In contrast, Central and Eastern Europe still struggle with limited reimbursement pathways, perpetuating unequal access gaps. MetabERN harmonizes clinical pathways across member states, easing cross-border knowledge transfer and bolstering adoption rates.

North America now represents the fastest-growing region, projected at a 15.7% CAGR through 2030, following the FDA's landmark 2024 green light. The United States leverages orphan-drug incentives and an expanding newborn-screening infrastructure exemplified by New Jersey's operational rollout. Canada and Mexico are aligning regulatory review procedures with US precedents, though differential pricing hurdles remain. Public debate over ultra-high-cost medicines intensifies pressure for outcome-based funding models, yet payer appetite for transformative rare-disease therapies persists.

Asia-Pacific and Latin America offer long-term upside, tempered by reimbursement constraints and limited infusion-center capacity. China's genomic newborn-screening pilot demonstrates technological readiness, recording lysosomal disorder detection at population scale. Japan participates actively in pivotal gene-therapy trials, which may accelerate domestic approval once global filings commence. Regional governments weigh the economic rationale of early detection against per-patient therapy costs, suggesting phased adoption as prices normalize. Collectively, geographic heterogeneity shapes a multi-speed growth pattern for the alpha-mannosidosis market.

1. Chiesi Farmaceutici
2. Sobi (Swedish Orphan Biovitrum)
3. Orchard Therapeutics plc
4. Avrobio
5. Ultragenyx Pharmaceutical Inc.
6. Regenxbio Inc.
7. Rocket Pharmaceuticals Inc.
8. M6P Therapeutics
9. SmartPharm Therapeutics
10. CSL Behring
11. Takeda Pharmaceuticals
12. JCR Pharmaceuticals
13. Leadiant Biosciences
14. ArmaGen Inc.
15. Sangamo Therapeutics
16. Astellas Gene Therapies
17. Bluebird Bio
18. Genethon
19. Passage Bio
20. Denali Therapeutics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support